
## Biomedical Ethics in U.S. Public Policy

## June 1993

OTA-BP-BBS-105 NTIS order #PB93-203768 GPO stock #052-003-01325-8



### **Recommended Citation:**

U.S. Congress, Office of Technology Assessment, *Biomedical Efhics in U.S. Public Policy —Background Paper, OTA-BP-BBS-105* (Washington, DC: U.S. Government Printing Office, June 1993).

## Foreword

ver the past two decades, a desire for mechanisms to articulate common values and foster consensus about biomedical advances in the face of cultural and religious heterogeneity resulted in the creation of Federal bioethics commissions. In hindsight, clearly some of these efforts have had lasting, measurable impacts. For over a decade, though, no such initiative has been functionally operational.

Recently, however, Congress has renewed its interest in a bioethics commission—signaling, in part, the increasing importance of medical and biological technologies in daily life. In September 1992, Senator Mark O. Hatfield, Ranking Minority, Committee on Appropriations; Senator Edward M. Kennedy, Chairman, Committee on Labor and Human Resources; and Senator Dennis DeConcini, Chairman, Subcommittee on Patents, Copyrights, and Trademarks, Committee on the Judiciary, asked the Office of Technology Assessment (OTA) to examine past, broad-based bioethics entities in the context of the question: If Congress decides to create a new Federal bioethics body, what does past experience reveal about which particular factors promote success and which should be avoided?

OTA prepared *Biomedical Ethics in U.S. Public Policy* with the assistance of workshop participants, contractors, and reviewers selected for their expertise and diverse points of view. Additionally, scores of individuals cooperated with OTA staff through interviews or by providing written material. OTA gratefully acknowledges the contribution of each of these individuals, As with all OTA Reports, however, responsibility for the content is OTA's alone,

The Report reviews the history of four Federal bioethics initiatives: the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, the Ethics Advisory Board, the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, and the Biomedical Ethics Advisory Committee. Today, as Congress considers whether to create a new Federal bioethics body, it can be guided by considering the strengths and weaknesses of these efforts. We believe that lessons from the past will prove instructive for the future. As the frontiers of biomedical research and technology continue to advance, it will become increasingly important for policymakers and the public to understand the ethical implications of such innovation.

Roger C. Herdman, Director

## Workshop Participants

**David Blumenthal,** *Workshop Chair* Massachusetts General Hospital Boston, MA

Adrienne Asch Boston University School of Social Work Boston, MA

Alexander M. Capron University of Southern California Law Center Los Angeles, CA

Robert M. Cook-Deegan Institute of Medicine Washington, DC

Ruth R. Faden Johns Hopkins University School of Hygiene and Public Health Baltimore, MD

**John C. Fletcher** University of Virginia Charlottesville, VA

Jonathan Glover Oxford University Oxford, United Kingdom

Patricia A. King Georgetown University Law Center Washington, DC **Bartha Maria Knoppers** University of Montreal Law Faculty Montreal, Canada

**Charles R. McCarthy** Kennedy Institute of Ethics Washington, DC

**Ellen H. Moskowitz** The Hastings Center Briarcliff Manor, NY

Gail J. Povar George Washington University Medical Center Washington, DC

**Donald W. Seldin** University of Texas Southwestern Medical School Dallas, TX

**David Shapiro** Nuffield Council on Bioethics London, United Kingdom

Michael S. Yesley Los Alamos National Laboratory Los Alamos, NM

**NOTE:** OTA appreciates and is grateful for the valuable assistance provided by the workshop participants. The workshop participants do not, however, necessarily approve, disapprove, or endorse this report. OTA assumes full responsibility for the report and the accuracy of its contents.

# **P**reject Staff

Robyn Y. Nishimi Project Director Ellen L. Goode Research Analyst

### **Michael Gough**

Program Manager Biological and Behavioral Sciences

**Cecile Parker** Office Administrator Linda Rayford-Journiette PC Specialist

Jene Lewis Administrative Secretary

## CONTRACTORS

Kathi E. Hanna Churchton, MD

**Constance M. Pechura** Editor Bethesda, MD

**Daniel J. Wikler** University of Wisconsin Madison, WI